N/A
- Pharmaceuticals
- Oculopharyngeal Muscular Dystrophy Treatment Market
Oculopharyngeal Muscular Dystrophy Treatment Market
Oculopharyngeal Muscular Dystrophy Treatment Market - Global Industry Analysis 2014 - 2018 and Forecast 2019 - 2029
Introduction
Oculopharyngeal Muscular Dystrophy (OPMD) is muscle disorder mainly affects the muscle of upper eye lids and throat. It is genetic condition characterized by muscle weakness and generally begins in adulthood. Oculopharyngeal muscular dystrophy is among the 30 inherited diseases declared by WHO and it result in weakening and worsening of muscles.
According to US Library of medicine, In Europe, the estimated prevalence of oculopharyngeal muscular dystrophy is 1 in 100,000 people. In French and Canadian population, it is more common where it is estimated to affect 1 in 1,000 individuals.
Rising prevalence of oculopharyngeal muscular dystrophy is anticipated to push the growth of oculopharyngeal muscular dystrophy treatment market during forecast period.
In February 2019, ‘Seelos Therapeutics’ a major key player involved in Oculopharyngeal Muscular Dystrophy treatment market, made an agreement with Bioblast Pharma Ltd., to acquire all development and commercial rights to Bioblast’s proprietary drug named trehalose which is predominantly used to treat Oculopharyngeal Muscular Dystrophy.
Oculopharyngeal Muscular Dystrophy treatment market is mainly contain various conventional drug therapies and novel gene therapies. Most of the novel therapies are under the product pipeline of major key players present in Oculopharyngeal Muscular Dystrophy treatment market.
Major driving factor involved in oculopharyngeal muscular dystrophy treatment market is increased prevalence of oculopharyngeal muscular dystrophy in middle aged population.
The conventional therapy mainly focused on symptomatic treatment of Oculopharyngeal Muscular Dystrophy and having lots of off target effects, this factor providing the additional opportunity for key players present in oculopharyngeal muscular dystrophy treatment market to expand their research and development activities and expected to drive the growth of oculopharyngeal muscular dystrophy treatment market.
Additionally, introduction of new disease-modifying and novel drugs therapies, increased drug development activities are expected to drive the oculopharyngeal muscular dystrophy treatment market.
Furthermore, gene therapies such as mutation suppression, exon skipping are also anticipated to push the oculopharyngeal muscular dystrophy treatment market during forecast period.
On the contrary, high cost of the novel therapies and lack of awareness among individuals are some factor that are expected to hamper the growth of oculopharyngeal muscular dystrophy treatment market.
The report covers exhaustive analysis on:
- Oculopharyngeal Muscular Dystrophy Treatment Market Segments
- Oculopharyngeal Muscular Dystrophy Treatment Market Dynamics
- Historical Actual Market Size, 2013 - 2017
- Oculopharyngeal Muscular Dystrophy Treatment Market Size & Forecast 2018 to 2024
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Report Highlights:
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
